Other: No treatment ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	1
274	Osteogenesis Imperfecta	1

53. Sjogren syndrome

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00631358 (ClinicalTrials.gov)	February 2008	29/2/2008	Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention		Sjogren's Syndrome	Drug: Maxidex;Other: No treatment	Alcon Research	NULL	Completed	17 Years	N/A	All	97	Phase 4	Canada

Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03638128 (ClinicalTrials.gov)	July 26, 2018	21/6/2018	Multicenter, Single-arm Open-label Extension Study to Assess Long-term Safety and Efficacy of Current or Prior Treatment With Denosumab in Children/Young Adults With Osteogenesis Imperfecta	Multicenter, Single-arm Open-label Extension Study to Assess Long-term Safety and Efficacy of Current or Prior Treatment With Denosumab in Children/Young Adults With Osteogenesis Imperfecta	Osteogenesis Imperfecta (OI)	Drug: Denosumab;Other: No treatment;Drug: Alternative osteoporosis medications	Amgen	NULL	Active, not recruiting	5 Years	20 Years	All	75	Phase 3	United States;Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom